Friday, June 2, 2017

A startup that charges $8,000 for young blood transfusions swears they’re worth every penny

And so it starts. This company is touting disease-fighting, but as I understand it the benefit that has been proven (at least in mice) is reduced senescence:

https://qz.com/996190/ambrosia-says-a-transfusion-of-young-blood-plasma-lowered-disease-markers-in-a-human-trial/

No comments:

MIT Mined Bacteria for the Next CRISPR—and Found Hundreds of Potential New Tools

https://singularityhub.com/2026/04/07/mit-mined-bacteria-for-the-next-crispr-and-found-hundreds-of-potential-new-tools/